Compare Nasdaq100 ETF (QQQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs ResMed Inc. — how do they compare? Nasdaq100 ETF trades at $715.5, while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. pays a 1.19% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| QQQ | RMD | |
|---|---|---|
52-Week High | $746.16 | $283.28 |
52-Week Low | $558.34 | $182.82 |
Market Cap | — | $31.89B |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $718.36, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains its position as a leading Nasdaq-100 tracker, though financial ratios are not applicable for this index fund structure. Recent news highlights ongoing institutional interest and comparisons with competing funds.
The outlook remains positive given the bullish technical setup and strong institutional backing. However, investors face risks from market volatility and fee structure comparisons with competing funds. The divided analyst consensus reflects uncertainty about near-term performance despite the fund's long-term growth trajectory.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
